Why Q32 Bio Inc.’s (QTTB) Stock Is Up 5.55%
As of Monday, October 12, Q32 Bio Inc.’s QTTB share price has surged by 5.55%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
Commentary & Analysis
Why Q32 Bio Inc.’s (QTTB) Stock Is Down 5.50%
As of Tuesday, October 06, Q32 Bio Inc.’s QTTB share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Q32 Bio Inc.’s (QTTB) Stock Is Up 5.15%
As of Friday, October 02, Q32 Bio Inc.’s QTTB share price has surged by 5.15%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Q32 Bio Inc.’s (QTTB) Stock Is Down 5.20%
As of Thursday, October 01, Q32 Bio Inc.’s QTTB share price has dipped by 5.20%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Q32 Bio Inc.’s (QTTB) Stock Is Down 9.13%
As of Wednesday, September 30, Q32 Bio Inc.’s QTTB share price has dipped by 9.13%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | QTTB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $248.3 | $242.6 | 30% |
|
| Shares Out (Mil) | 20.3 | 54.0 | 31% |
|
| Institutional Ownership | 97.5% | 93.1% | 74% |
|
| Float (Mil) | 14.6 | 41.4 | 24% |
|
| Beta | -0.38 | 0.95 | 2% |
|
| Avg Daily Volume (000s) | 1,628 | 633 | 78% |
|
| Price Change (52-week) |
178.9% | 50.0% | 98% |
|
| Growth | QTTB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | QTTB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $54 | $37 | 20% |
|
| Net Income (TTM) (Mil) | $34 | ($44) | 52% |
|
| EPS (TTM) | $2.277 | ($1.600) | 74% |
|
| Operating Cash Flow (TTM) (Mil) | ($20) | ($34) | 15% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 24% |
|
| Enterprise Value (Q1) (Mil) | $160 | $177 | 24% |
|
| Valuation | QTTB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.87 | 2.33 | 50% |
|
| P/E | 3.7 | 19.6 | 3% |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | QTTB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 73.3% | 67.3% | 84% |
|
| Net Margin | 62.9% | (74.8%) | 98% |
|
| ROA | 37.1% | (47.6%) | 99% |
|
| ROE | 72.1% | (54.9%) | 95% |
|
| Liabilities to Assets | 8.6% | 29.3% | 5% |
|
| F-Score | 4 | 3 | 33% |
|
Passing Stock Screens
As of 10/9/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Fundamental Rule of Thumb Screen
Factors: Value
An old value screen combining the P/E ratio, dividend yield, and an adjusted return on equity that's still applicable in today's market.
| Performance Since Inception: | 6.3% |
| +/- S&P 500: | -1.2 |
